MCG In Long QT Syndrome
ConditionAtrial Fibrillation
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
The primary objective of this observational study is to evaluate whether magnetocardiography (MCG) findings more accurately predict clinical outcomes in patients with acquired Long QT syndrome compared to ECG. The secondary objective is to assess differences in QT interval length between MCG and ECG. The primary safety objective is to characterize the safety profile of the CardiAQ MCG device.
Eligibility criteria
Qualifiers
Age ≥ 18 years on the date of consent
Ability for participant to comply with study requirements
Written informed consent
Confirmed diagnosis of atrial fibrillation and receiving dofetilide for rhythm control in the inpatient setting.
Disqualifiers
Pregnant or breastfeeding
Active thoracic metal implants (including pacemaker, insertable cardiac monitor, or internal defibrillators).
External electrical pads or devices (e.g. Pacer pads, ECG electrodes, heart rate patch), that must remain on patient's chest during MCG scan
Inability to lie down in a supine/inclined position and stay still on the examination bed
Trial design
Treatments tested in this trial
- Magnetocardiography
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov